These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25974248)

  • 1. Structural diversity of the epigenetics pocketome.
    Cabaye A; Nguyen KT; Liu L; Pande V; Schapira M
    Proteins; 2015 Jul; 83(7):1316-26. PubMed ID: 25974248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting of chromatin: status and opportunities.
    Siklos M; Kubicek S
    FEBS J; 2022 Mar; 289(5):1276-1301. PubMed ID: 33982887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtual screening and biological evaluation of novel small molecular inhibitors against protein arginine methyltransferase 1 (PRMT1).
    Xie Y; Zhou R; Lian F; Liu Y; Chen L; Shi Z; Zhang N; Zheng M; Shen B; Jiang H; Liang Z; Luo C
    Org Biomol Chem; 2014 Dec; 12(47):9665-73. PubMed ID: 25348815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone modification enzymes: novel targets for cancer drugs.
    Kristeleit R; Stimson L; Workman P; Aherne W
    Expert Opin Emerg Drugs; 2004 May; 9(1):135-54. PubMed ID: 15155140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development.
    Rogawski DS; Grembecka J; Cierpicki T
    Future Med Chem; 2016 Sep; 8(13):1589-607. PubMed ID: 27548565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein arginine methyltransferases (PRMTs): role in chromatin organization.
    Jahan S; Davie JR
    Adv Biol Regul; 2015 Jan; 57():173-84. PubMed ID: 25263650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Druggability of methyl-lysine binding sites.
    Santiago C; Nguyen K; Schapira M
    J Comput Aided Mol Des; 2011 Dec; 25(12):1171-8. PubMed ID: 22146969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical profiling of the genome with anti-cancer drugs defines target specificities.
    Pang B; de Jong J; Qiao X; Wessels LF; Neefjes J
    Nat Chem Biol; 2015 Jul; 11(7):472-80. PubMed ID: 25961671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical advances in targeting epigenetics for cancer therapy.
    Feng S; De Carvalho DD
    FEBS J; 2022 Mar; 289(5):1214-1239. PubMed ID: 33545740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromodomain biology and drug discovery.
    Zaware N; Zhou MM
    Nat Struct Mol Biol; 2019 Oct; 26(10):870-879. PubMed ID: 31582847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule inhibitors that discriminate between protein arginine N-methyltransferases PRMT1 and CARM1.
    Dowden J; Pike RA; Parry RV; Hong W; Muhsen UA; Ward SG
    Org Biomol Chem; 2011 Oct; 9(22):7814-21. PubMed ID: 21952734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pocketome: an encyclopedia of small-molecule binding sites in 4D.
    Kufareva I; Ilatovskiy AV; Abagyan R
    Nucleic Acids Res; 2012 Jan; 40(Database issue):D535-40. PubMed ID: 22080553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [What is epigenetics? Strategies for research and application to cancer].
    Van Seuningen I
    Ann Pathol; 2009 Nov; 29 Spec No 1():S28-30. PubMed ID: 19887245
    [No Abstract]   [Full Text] [Related]  

  • 14. Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer.
    Verma SK; Knight SD
    Future Med Chem; 2013 Sep; 5(14):1661-70. PubMed ID: 24047271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
    Gentile F; Tuszynski JA; Barakat KH
    J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based grafting and identification of kinase-inhibitors to target mTOR signaling pathway as potential therapeutics for glioblastoma.
    Cui YH; Chen J; Xu T; Tian HL
    Comput Biol Chem; 2015 Feb; 54():57-65. PubMed ID: 25625417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-covalent Metallo-Drugs: Using Shape to Target DNA and RNA Junctions and Other Nucleic Acid Structures.
    Cardo L; Hannon MJ
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer epigenetics: promises and pitfalls for cancer therapy.
    Skourti E; Dhillon P
    FEBS J; 2022 Mar; 289(5):1156-1159. PubMed ID: 35233949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic drugs that do not target enzyme activity.
    Owen DR; Trzupek JD
    Drug Discov Today Technol; 2014 Jun; 12():e29-34. PubMed ID: 25027371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competitive binding of a benzimidazole to the histone-binding pocket of the Pygo PHD finger.
    Miller TC; Rutherford TJ; Birchall K; Chugh J; Fiedler M; Bienz M
    ACS Chem Biol; 2014 Dec; 9(12):2864-74. PubMed ID: 25323450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.